We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
MNA
326
Manning & Napier Advisors
New York
$31.5M -$2.81M -96,627 -8%
VFAM
327
Valley Forge Asset Management
Pennsylvania
$31.3M -$25.6M -877,935 -45%
GI
328
GLG Inc
New York
$31M +$7.73M +265,601 +33%
Connor, Clark & Lunn Investment Management (CC&L)
329
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$29.9M +$16.2M +556,617 +135%
BPBT
330
Boston Private Bank & Trust
Massachusetts
$29.9M +$1.2M +41,069 +4%
PP
331
Prospector Partners
Connecticut
$29.8M -$27.6M -947,177 -48%
EIP
332
Epoch Investment Partners
New York
$29.6M +$138K +4,732 +0.5%
QBFM
333
QS Batterymarch Financial Management
New York
$29.4M -$2.77M -95,022 -9%
MMH
334
Menora Mivtachim Holdings
Israel
$28.5M
CC
335
Chubb Corp
New Jersey
$28.1M
SIM
336
Sadoff Investment Management
Wisconsin
$27.7M +$63K +2,166 +0.2%
WAM
337
World Asset Management
Michigan
$27.7M -$5.23M -179,726 -16%
ABI
338
Abrams Bison Investments
Maryland
$27.6M
RCM
339
Riverhead Capital Management
Delaware
$27M +$4.84M +166,430 +22%
ISL
340
Ingalls & Snyder LLC
New York
$27M -$42.9K -1,475 -0.2%
B
341
Baird
Wisconsin
$26.8M -$1.49M -51,273 -5%
ICM
342
ICC Capital Management
Florida
$26.7M -$10.7M -367,940 -29%
NC
343
Nicholas Company
Wisconsin
$26.5M +$411K +14,123 +2%
MAM
344
Martingale Asset Management
Massachusetts
$26.4M +$3.57M +122,825 +16%
CIM
345
Confluence Investment Management
Missouri
$26.2M +$2.26M +77,542 +9%
BII
346
Baring International Investment
United Kingdom
$25.8M -$7.27M -249,634 -22%
PHS
347
PFM Health Sciences
California
$25.6M -$80.3M -2,758,675 -76%
MOACM
348
Mutual of America Capital Management
New York
$25.2M -$213K -7,303 -0.8%
GKIM
349
GW&K Investment Management
Massachusetts
$25M +$392K +13,466 +2%
Zurich Cantonal Bank
350
Zurich Cantonal Bank
Switzerland
$24.9M -$3.14M -107,953 -11%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.